Innovent Biologics to launch China's first Mazdutize injection next year

China's first Mazdutize injection is about to hit the market next year. [Photo/WeChat ID: hongqiaoshangwuqu]

Innovent Biologics (Shanghai) Global R&D Center, located in the Qianwan area of the Shanghai Hongqiao International Central Business District, is set to launch China's first Mazdutize injection next year.

This innovative medication offers dual benefits of weight loss and blood sugar control, while also protecting cardiovascular health and reducing liver fat.

The announcement follows Innovent Biologics' recent expansion into Hongqiao this past August, highlighting the company's commitment to global growth and affordable biopharmaceuticals.

Biomedicine is a key industry in Shanghai, with the Qianwan area developing into a new hub for the biopharmaceutical sector in the Yangtze River Delta region. The Mazdutize injection has already generated significant excitement within the industry.

Lei Qian, senior vice-president of Clinical Development at Innovent Biologics, explained the injectio's benefits: "This medication protects cardiovascular health, suppresses gastrointestinal motility to induce fullness, reduces appetite, and stimulates insulin release to lower blood sugar levels. It also targets liver fat, significantly alleviating fatty liver, and helps reduce blood pressure, blood lipids, and blood uric acid levels."

By 2030, over 600 million people in China are expected to be affected by obesity or overweight issues. Mazdutize, a dual-target GLP-1 and glucagon receptor agonist, has been in development for nearly a decade and is currently under review by the National Medical Products Administration.

Innovent Biologics aims to provide high-quality, affordable biopharmaceuticals. To date, the company has had 11 products approved for market release, with 18 new drug candidates in clinical trials.

Innovent Biologics (Shanghai) Global R&D Center. [Photo/WeChat ID: hongqiaoshangwuqu]